Multiple Myeloma Coverage from Every Angle

Recent News

Which Patients With Myeloma Benefit From Autologous Stem Cell Transplantation?
Myelomatous Pleural Effusion at Time of Initial Diagnosis of Myeloma: Case Report
New Receptor Protein May Successfully Target Multiple Myeloma Cells
Overall Survival With Daratumumab-Based Regimen in Myeloma
Isatuximab-irfc Combination Therapy for Multiple Myeloma Approved by FDA
Study Sheds Light on Genetic Landscape of Resistant Multiple Myeloma
Daratumumab-Based Combination Therapy for Newly Diagnosed Multiple Myeloma
Phase I Trial Results With Immunotherapy bb21217 for Resistant Multiple Myeloma
Dana-Farber Receives $16.5 Million Gift to Support Multiple Myeloma Research
Combination Therapy for Frail and Unfit Patients Newly Diagnosed With Multiple Myeloma
Belantamab Mafodotin Granted Priority Review by FDA for Resistant Multiple Myeloma
Dual-Target CAR T-Cell Therapy in Resistant Multiple Myeloma
Venetoclax in Combination With Dexamethasone for Resistant Multiple Myeloma
Novel Monoclonal Antibody in Relapsed or Refractory Multiple Myeloma
Ixazomib-Based Combination for High-Risk Smoldering Multiple Myeloma
Is Ixazomib/Dexamethasone a New Option for Treating AL Amyloidosis?
ASH 2019: Dose-Finding Study of Novel Immunotherapy for Resistant Myeloma
ASH 2019: Early Trial Results With CAR T-Cell Therapy for Resistant Myeloma
ASH 2019: Characterizing Molecular Drivers of Myeloma Cells Via CRISPR Activation
ASH 2019: Addition of Selinexor to Treatment Regimen for Resistant Myeloma
ASH 2019: CANDOR Trial of Daratumumab Combination Therapy for Resistant Myeloma
ASH 2019: Early Results With Multiplexed Genetic Engineering in Treating Multiple Myeloma
STORM Trial: Oral Selinexor Combination in Refractory Myeloma
Carfilzomib-Based Therapy for Transplant-Eligible Patients With Myeloma
Transitioning From Bortezomib to Ixazomib in Multiple Myeloma
Daratumumab Plus Triplet Therapy for Transplant-Eligible Patients With Multiple Myeloma
Combination Therapy With Venetoclax in Resistant Multiple Myeloma
Early-Phase Trial of New Monoclonal Antibody Plus Pembrolizumab in Resistant Myeloma
Comparison of First-Line Treatments in Older Patients With Myeloma
Melflufen-Based Combination Therapy for Resistant Myeloma
Combination Therapy With Selinexor, Lenalidomide, and Dexamethasone in Resistant Myeloma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.